Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 3Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 1

Conditions

Neoplasms 4Pancreatic Neoplasms 2Digestive System Neoplasms 2Pancreatic cancer, adult 1Pancreatic Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Endocrine Gland Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × napabucasin × Clear all
NCT01775423 2023-11-14

A Study of BBI608 in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
87 enrolled
Tumor-Agnostic

Neoplasms

NCT02467361 2023-11-14

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

Sumitomo Pharma America, Inc.

Phase 1 Completed
104 enrolled
Tumor-Agnostic

Neoplasms

NCT02432326 2023-11-08

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Sumitomo Pharma America, Inc.

Phase 1 Completed
147 enrolled
Tumor-Agnostic

Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡